• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Moxifloxacin Free Base

Moxifloxacin Free Base

Product ID M5793
Cas No. 151096-09-2
Purity ≥98%
Product Unit SizeCostQuantityStock
100 mg $195.00 In stock
500 mg $681.00 In stock
1 g $875.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Moxifloxacin is a fluoroquinolone antibiotic commonly used to treat ocular infections such as bacterial conjunctivitis as well as sinus and lung infections such as pneumonia. Moxifloxacin displays antibacterial efficacy against both gram negative and gram positive bacteria, preventing DNA synthesis in bacterial pathogens by inhibiting topoisomerase IV and bacterial DNA gyrase. This compound is currently being examined as a conjunctive therapy with anticancer agents against several forms of cancer due to its topoisomerase II inhibition. Combining moxifloxacin with anticancer agents yields a cytotoxic drug sparing effect due to the synergism of the mechanisms of action between moxifloxacin and the anticancer drugs.

Product Info

Cas No.

151096-09-2

Purity

≥98%

Formula

C21H24FN3O4

Formula Wt.

401.43

IUPAC Name

7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3, 4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3- carboxylic acid

Solubility

Water: 1.5mg/mL Ethanol: 5mg/mL DMSO: 15mg/mL

Appearance

Yellow Solid

Shipping and Storage

Store Temp

4°C

Ship Temp

Ambient

Downloads

MSDS

M5793 MSDS PDF

Info Sheet

M5793 Info Sheet PDF

References

Wohlkonig A, Chan PF, Fosberry AP, et al. Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol. 2010 Sep;17(9):1152-3. PMID: 20802486.

Reuveni D, Halperin D, Shalit I, et al. Moxifloxacin enhances etoposide-induced cytotoxic, apoptotic and anti-topoisomerase II effects in a human colon carcinoma cell line. Int J Oncol. 2010 Aug;37(2):463-71. PMID: 20596674.

Reuveni D, Halperin D, Fabian I, et al. Moxifloxacin increases anti-tumor and anti-angiogenic activity of irinotecan in human xenograft tumors. Biochem Pharmacol. 2010 Apr 15;79(8):1100-7. PMID: 20025849.

Laponogov I, Sohi MK, Veselkov DA, et al. Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat Struct Mol Biol. 2009 Jun;16(6):667-9. PMID: 19448616.

Stroman DW, Dajcs JJ, Cupp GA, et al. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone. Surv Ophthalmol. 2005 Nov;50 Suppl 1:S16-31. PMID: 16257308.

Aldred KJ, McPherson SA, Wang P, et al. Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance. Biochemistry. 2012 Jan 10;51(1):370-381. PMID: 22126453.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • R1860

    Repaglinide

    Sulfonylurea; ATP-sensitive K+ channel blocker....

    ≥98%
  • N9874

    Nystatin

    Polyene macrolide, induces pore formation in fu...

    4400u/mg
  • M4000

    MK-2206 Monohydrochloride

    Akt inhibitor.

    ≥99%
  • A5472

    Ansamitocin P3

    Microtubule depolymerization inhibitor.

    ≥70% (P3), Total Ansamitocins ≥95%
  • P6858

    Procarbazine Hydrochloride

    Hydrazine derivative, DNA alkylator; MAO inhibi...

    ≥97%
  • T2801

    Thapsigargin

    Sesquiterpene lactone found in Thapsia, used to...

    ≥98%
  • E7668

    Etretinate

    Aromatic retinoid; RAR, RXR agonist.

    ≥98%
  • E7310

    Esculin

    Coumarin glucoside found in Aesculus, Daphne, a...

    ≥98%
  • C179602

    CEP-28122

    ALK inhibitor.

    ≥98%
  • L1884

    Levosimendan

    Ca2+ sensitizer; ATP-sensitive K+ channel activ...

    ≥98%
  • T564098

    Tocored

    Tocopherol analog

  • G4634

    Glipizide

    Sulfonylurea; ATP-sensitive K+ channel blocker....

    ≥98%
  • E4902

    Emamectin B1 Benzoate

    Semi-synthetic avermectin; GABA potentiator.

    ≥80%
  • I0416

    Iberin

    Isothiocyanate found in cruciferous vegetables,...

    ≥97%
  • T342710

    Tirzepatide

    GLP-1/GIP receptor co-agonist

    ≥98%
  • Z1970

    Zerumbone

    Cyclic sesquiterpene found in ginger root; pote...

    ≥99%
  • C0824

    CCG1423

    Serum response factor inhibitor and MRTF-A bind...

    ≥98%
  • P1200

    PD-184352

    MEK1/2 and Raf inhibitor.

    ≥98%
  • C086007

    CC-671

    TTK/CLK2 inhibitor.

    ≥98%
  • D3362

    Dipyridamole

    PDE and adenosine deaminase inhibitor.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2026 LKT Laboratories, All Rights Reserved - Products for research use only